Filing Flows › Veracyte (VCYT) › How it makes money
How Veracyte (VCYT) makes money
Veracyte (VCYT) made $152M of revenue in the third quarter 2026 (Q3 2026), +15% from a year earlier. Testing revenue brought in $146M (96%); Product revenue brought in $4.6M (3%); Biopharmaceutical and other revenue brought in $709K (0%). Of every dollar of revenue, 71¢ was left as gross profit, 11¢ was left as operating profit, 21¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Testing revenue | $146M | 96.5% | +0.5% | +15% |
| Product revenue | $4.6M | 3.0% | +20% | +40% |
| Biopharmaceutical and other revenue | $709K | 0.5% | -12% | -13% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $152M | 100.0% |
| Cost of revenue | $44.6M | 29.4% |
| Gross profit | $107M | 70.6% |
| Operating expenses | $90.5M | 59.7% |
| Operating profit | $16.6M | 10.9% |
| Net earnings | $31.5M | 20.8% |
| Operating cash flow | $40.3M | 26.5% |
| Free cash flow | $37.9M | 25.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $152M | +15% |
| Q2 2026 | $150M | +16% |
| Q1 2026 | $139M | +22% |
| Q4 2025 | $141M | +18% |
| Q3 2025 | $132M | +14% |
| Q2 2025 | $130M | +14% |
| Q1 2025 | $114M | +18% |
From Veracyte's 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Veracyte make money?
Veracyte (VCYT) made $152M of revenue in the third quarter 2026 (Q3 2026), +15% from a year earlier. Testing revenue brought in $146M (96%); Product revenue brought in $4.6M (3%); Biopharmaceutical and other revenue brought in $709K (0%). Of every dollar of revenue, 71¢ was left as gross profit, 11¢ was left as operating profit, 21¢ was left as net earnings.
What is Veracyte's biggest business?
Testing revenue: $146M in the third quarter 2026, 96% of revenue, +15% from a year earlier.
What is Veracyte's profit margin?
Net earnings were $31.5M, 20.8% of revenue, in the third quarter 2026; the operating margin was 10.9%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.